Blise, Katie E. http://orcid.org/0000-0002-6433-9455
Sivagnanam, Shamilene http://orcid.org/0000-0001-5966-1522
Banik, Grace L. http://orcid.org/0000-0002-0075-4334
Coussens, Lisa M. http://orcid.org/0000-0003-2389-1865
Goecks, Jeremy http://orcid.org/0000-0002-4583-5226
Funding for this research was provided by:
Knight Cancer Institute, OHSU; Prospect Creek Foundation to the OHSU SMMART Program
U.S. Department of Health & Human Services | NIH | National Cancer Institute (T32CA254888, R01CA223150, R01CA226909, R21HD099367, U2CCA233280, U01CA224012)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Brenden-Colson Center for Pancreatic Care, OHSU; Knight Cancer Institute, OHSU; Prospect Creek Foundation to the OHSU SMMART Program
Article History
Received: 14 May 2021
Accepted: 7 January 2022
First Online: 25 February 2022
Competing interests
: L.M. Coussens is a paid consultant for Cell Signaling Technologies, AbbVie Inc., and Shasqi Inc., received reagent and/or research support from Plexxikon Inc., Pharmacyclics, Inc., Acerta Pharma, LLC, Deciphera Pharmaceuticals, LLC, Genentech, Inc., Roche Glycart AG, Syndax Pharmaceuticals Inc., Innate Pharma, NanoString Technologies, and Cell Signaling Technologies, is a member of the Scientific Advisory Boards of Syndax Pharmaceuticals, Carisma Therapeutics, Zymeworks, Inc, Verseau Therapeutics, Cytomix Therapeutics, Inc., Hibercell., Inc., Alkermes, Inc., and Kineta Inc, and is a member of the Lustgarten Therapeutics Advisory working group. No competing interests were disclosed by the other authors.